Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril: Effects of adherence and duration of drug action on outcomes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients miss occasional doses of antihypertensives. The use of 'forgiving' drugs (i.e. drugs with duration of action longer than the 24-h dosing interval) may allow an adequate blood pressure (BP) reduction to be maintained despite missed doses. AIM: To quantify the effects of adherence level and duration of action on estimated mean systolic BP (SBP) reduction and cardiovascular disease (CVD) risk. METHOD: For 1250 patients, we simulated 256-day dosing histories with realistically distributed drug holidays based on a study of electronically monitored dosing records. Adherence was set to the desired level by altering the proportion of doses missed. Mean office SBP-lowering effect (aliskiren 300 mg, -14.1 mmHg; irbesartan 300 mg, -13.3; ramipril 10 mg, -10.1 mmHg) and the rate of SBP increase after stopping treatment (off-rate; aliskiren, 1.0 mmHg/day; irbesartan, 3.6 mmHg/day; ramipril, 4.0 mmHg/day) were taken from the results of a randomised, double-blind trial. SBP was averaged over time and patient to estimate mean reductions in SBP and 10-year CVD risk (Framingham risk equation, baseline absolute 10-year CVD risk: 27%). RESULTS: Predicted reductions in SBP and CVD risk with aliskiren were larger and less affected by imperfect adherence than the reductions with irbesartan or ramipril. For aliskiren, reducing adherence from 90% to 60% led to a predicted rise in SBP of 1.0 mmHg and three additional CVD events per 1000 treated patients; larger predicted differences were observed for irbesartan (2.5 mmHg; 7.5 events/1000 treated patients) and ramipril (2.2 mmHg; 6.7 events/1000 treated patients). CONCLUSION: To offset the effects of imperfect adherence, a common challenge with antihypertensives, for better BP management it may be prudent to prescribe 'forgiving' drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs
Dragomir, A., Côté, R., Roy, L., Blais, L., Lalonde, L., Bérard, A., & Perreault, S. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d567bd · Cited by 221
Taylor, A. A., & Shoheiber, O. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2003.03269.x · Cited by 151
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationWilliams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Self-citationAdherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Self-citationMeasuring, Analyzing, and Managing Drug Adherence in Resistant Hypertension
Burnier, M., Wuerzner, G., Struijker-Boudier, H., & Urquhart, J. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.00687 · Cited by 229
Self-citation
Metadata
- Authors
- Burnier, M., Brede, Y., & Lowy, A.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2011-01-06
- Volume
- 65
- Issue
- 2
- Pages
- 127-133
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W2143657807
- Cited by
- 28
- References
- 4
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril: Effects of adherence and duration of drug action on outcomes. https://app.cochat.ai/papers/10.1111/j.1742-1241.2010.02616.x
- The paper
- Burnier, M., Brede, Y., & Lowy, A. (2011). Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril: Effects of adherence and duration of drug action on outcomes. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2010.02616.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.